Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Hosted on MSN
Epic oops
This epic fails compilation is a masterclass in misplaced confidence and instant consequences. Republican warns Trump admin move "disastrous" for security New class of warship to be named after Trump ...
TIOBE Index for January 2026: Top 10 Most Popular Programming Languages Your email has been sent January’s TIOBE Index begins the year with familiar names still setting the pace, but the underlying ...
Minnie Mouse tells you that the Phonograph the Fairy Godmother enchanted seems to be having issues. Head to her home and take a picture of the problem. Speak with the Fairy Godmother. She will thank ...
There are enviable individuals who acquire skills and knowledge effortlessly, others are more orderly and achievement-focused than are their peers, and still others who exhibit unusual talents. While ...
Carol M. Kopp edits features on a wide range of subjects for Investopedia, including investing, personal finance, retirement planning, taxes, business management, and career development. Khadija ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback